Robert D. Bachman
Merck & Co., Inc., Rahway, NJ, USA (United States) · 12 works · 895 citations · h-index 9
Top works
- Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
- Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
- Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
- A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
- Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.
- Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design
- Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
- Phenotypic and imaging features of FLNA-negative patients with bilateral periventricular nodular heterotopia and epilepsy
- Long‐Term Open‐Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs
- Efficacy and Tolerability of Rizatriptan for Treatment of a Single Migraine Attack in Pediatric Migraineurs: Results from a Randomized, Double-Blind, Placebo-Controlled Trial Using a Novel Enrichment Design (P03.240)
- Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel enrichment design
- Long-Term Safety and Tolerability of Rizatriptan for Intermittent Acute Treatment of Migraine in Pediatric Migraineurs (P03.232)